You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Congresses

Congress Materials

Access abstracts, posters, and presentations presented at the following congresses

June 2024

European Hematology Association (EHA)

European Hematology Association (EHA)

June 2024 (Madrid, Spain)

Abstracts

Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis Matching-adjusted indirect comparison (MAIC) of zanubrutinib versus real-world chemoimmunotherapy (CIT) or chemotherapy (Chemo) in relapsed/refractory marginal zone lymphoma (R/R MZL) Zanubrutinib vs other Bruton’s tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia: a multilevel network meta-regression Zanubrutinib vs. acalabrutinib in B-cell malignancies: an adverse event-based economic analysis BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naive (TN) CLL Combination of zanubrutinib + venetoclax for treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D Combination treatment with novel BCL-2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) Efficacy and safety of zanubrutinib vs. venetoclax+ibrutinib in the treatment-naïve (TN) chronic lymphocytic leukemia (CLL): a matching-adjusted indirect comparison (MAIC) Efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC) Indirect comparison of efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed/refractory mantle cell lymphoma Intrapatient comparative analysis of zanubrutinib plus obinutuzumab efficacy in relapsed/refractory follicular lymphoma using the growth modulation index Patient-reported outcome (PRO)–based recurrent symptomatic deterioration predicts disease progression: results from the ALPINE trial Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) indolent NHL: results from the phase 1 BGB-16673-101 study Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naive patients with acute myeloid leukemia Real-world Bruton tyrosine kinase inhibitor treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in us community oncology practices Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma Real-world comparative effectiveness of covalent Bruton tyrosine kinase inhibitors (cBTKi) among patients with relapsed/refractory mantle cell lymphoma (R/R MCL) Real-world evaluation of treatment patern, time to next treatment, healthcare resource utilization, and cost of care in follicular lymphoma Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL Recent patterns of care with btk inhibitors and distribution of social determinants of health among patients with cll/sll in the us community setting Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses Risk of hypertension in patients with CLL/SLL who participated in ALPINE: a post hoc analysis Risk of new-onset hypertension in newly diagnosed chronic lymphocytic leukemia patients treated with Bruton tyrosine kinase inhibitors: a real-world study using the Symphony Health Solutions database Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström's macroglobulinemia Sonrotoclax plus dexamethasone is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma harboring t(11;14)
May 2024

International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

May 2024 (Atlanta, Georgia)
April 2024

British Society for Haematology (BSH)

British Society for Haematology (BSH)

April 2024 (Liverpool, United Kingdom)
April 2024

Academy of Managed Care Pharmacy (AMCP)

April 2024

International Society for Pharmacoepidemiology (ISPE)

April 2024

American Association for Cancer Research (AACR)

American Association for Cancer Research (AACR)

April 2024 (San Diego, California, USA)

Posters

A first-in-human, phase 1a, dose-escalation study of BGB-10188, a phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, + tislelizumab (anti-PD-1) in patients with solid tumors BGB-A317-LBL-007-202: a phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL-007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as first-line (1L) treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) BGB-B167, a first-in-class 4-1BB/ CEACAM5 bispecific antibody, exhibits potent in vitro and vivo antitumor activity and superior safety profile in preclinical models BGB-LC-201 (NCT05635708): a phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non–small cell lung cancer (NSCLC) Characterization of the correlation between BTK degradation and tumor growth inhibition of the BTK target protein degraders using PK/PD modeling Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD1) in 1L PD-L1+ non-small cell lung cancer (NSCLC) Liberty-201: maintenance fluoropyrimidine (FP) and bevacizumab with or without anti-lymphocyte activation gene-3 (LAG-3) antibody LBL-007 plus anti-programmed cell death protein-1 (PD-1) antibody tislelizumab (TIS) for patients (pts) with metastatic or unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) colorectal cancer (CRC) Translational assessment of triple combination with tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and clinical potential in solid tumors such as HNSCC

Abstracts

A first-in-human, phase 1a, dose-escalation study of BGB-10188, a phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, + tislelizumab (anti-PD-1) in patients with solid tumors AdvanTIG-204: a phase 2, multicenter, randomized, 3-arm, open-label study investigating the preliminary efficacy and safety of ociperlimab (anti-TIGIT) + tislelizumab (anti-PD-1) + concurrent chemoradiotherapy (cCRT) in patients with untreated limited-stage small cell lung cancer (SCLC) BGB-A317-LBL-007-202: a phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL-007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as first-line (1L) treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) BGB-B167, a first-in-class 4-1BB/ CEACAM5 bispecific antibody, exhibits potent in vitro and vivo antitumor activity and superior safety profile in preclinical models BGB-LC-201 (NCT05635708): a phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non–small cell lung cancer (NSCLC) Characterization of the correlation between BTK degradation and tumor growth inhibition of the BTK target protein degraders using PK/PD modeling Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD1) in 1L PD-L1+ non-small cell lung cancer (NSCLC) Liberty-201: maintenance fluoropyrimidine (FP) and bevacizumab with or without anti-lymphocyte activation gene-3 (LAG-3) antibody LBL-007 plus anti-programmed cell death protein-1 (PD-1) antibody tislelizumab (TIS) for patients (pts) with metastatic or unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) colorectal cancer (CRC) Translational assessment of triple combination with tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and clinical potential in solid tumors such as HNSCC
April 2024

Hematology/Oncology Pharmacy Association (HOPA)

Hematology/Oncology Pharmacy Association (HOPA)

April 2024 (Tampa, Florida, USA)
March 2024

Korean Society of Hematology International Conference and 65th Annual Meeting (ICKSH)

March 2024

44th Congress of the French Society of Hematology (SFH)

44th Congress of the French Society of Hematology (SFH)

March 2024 (Paris, France)

Abstracts

Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) that progressed in the ALPINE study Efficacité similaire de l’ibrutinib dans les essais ALPINE et ELEVATE-RR sur la leucémie lymphoïde chronique en rechute/réfractaire : comparaison indirecte ajustée par appariement Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL) First results from a phase 1, first-in-human study of the bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory B-cell malignancies Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma (R/R FL) treated with zanubrutinib + obinutuzumab versus obinutuzumab monotherapy: the ROSEWOOD trial Le suivi prolongé de l’étude de phase 3 randomisée ALPINE confirme que le zanubrutinib présente une supériorité à long terme sur le plan de la survie sans progression par rapport à l’ibrutinib dans le traitement de la LLC/LPL R/R Mutations acquises chez des patients atteints de leucémie lymphoïde chronique (LLC) en rechute/réfractaire ayant progressé dans l’étude ALPINE Outcomes ≥1 year after transitioning from treatment with ibrutinib in the ASPEN study to zanubrutinib Premiers résultats d’une étude de phase 1 évaluant le BGB-16673, un dégradeur de la tyrosine kinase de Bruton, chez des patients atteints d’hémopathies lymphoïdes B en rechute/réfractaire Qualité de vie liée (QdV) chez les patients atteints d’un lymphome folliculaire en rechute/réfractaire (LF R/R) traités par zanubrutinib + obinutuzumab par rapport à obinutuzumab en monothérapie : l’essai ROSEWOOD Résultats à ≥ 1 an chez les patients ayant reçu zanubrutinib après un traitement par ibrutinib dans l’étude ASPEN Similar ibrutinib efficacy in ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: matching-adjusted indirect comparison Sonrotoclax (BGB-11417) + zanubrutinib chez des patients présentant une leucémie lymphoide chronique / un lymphome lymphocytique (LLC/LL) non prétraités : essai de phase 1/2 en cours Sonrotoclax (BGB-11417) + zanubrutinib in patients with treatment-naive CLL/SLL: an ongoing phase 1/2 study Tislelizumab, an anti–PD-1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: A prospective, multicenter, phase 2 LYSA study conducted in Western countries Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed/refractory chronic lymphocytic leukemia Toxicité, survie sans progression et qualité de vie des patients traités par zanubrutinib par rapport à ibrutinib dans la leucémie lymphoïde chronique en rechute/réfractaire : analyse Q-TWiST de l’étude ALPINE Zanubrutinib chez des patients intolérants à l’acalabrutinib atteints d’hémopathies lymphoïdes B Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies Évaluation du tislélizumab, anticorps anti-PD-1, chez des patients atteints d’un lymphome de Hodgkin classique en rechute/ réfractaire : étude prospective multicentrique de phase 2 TIRHOL BGB-A317-210 du LYSA
March 2024

European Lung Cancer Congress (ELCC)

March 2024

European School of Haematology's 3rd Translational Research Conference: Chronic Lymphocytic Leukaemia (ESH CLL)

European School of Haematology's 3rd Translational Research Conference: Chronic Lymphocytic Leukaemia (ESH CLL)

March 2024 (Vienna, Austria)
February 2024

International Congress on Hematologic Malignancies (ICHM)

International Congress on Hematologic Malignancies (ICHM)

February 2024 (Miami Beach, Florida, USA)
February 2024

Japanese Society of Medical Oncology (JSMO)

February 2024

European Society for Medical Oncology Virtual Plenary (ESMO)

January 2024

Congrès de Pneumologie de Langue Française (CPLF)

January 2024

Biennale Monégasque de Cancérologie (BMC)

January 2024

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (ASCO-GI)

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (ASCO-GI)

January 2024 (San Francisco, California, USA)
December 2023

American Society of Hematology (ASH)

American Society of Hematology (ASH)

December 2023 (San Diego, California, USA)

Posters

Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia who progressed in the ALPINE study Broad superiority of zanubrutinib over bendamustine + rituximab across multiple high-risk factors: biomarker subgroup analysis in the phase 3 SEQUOIA study in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma without del(17p) Clinical outcomes in patients with Waldenström macroglobulinemia (WM) receiving ibrutinib on the phase 3 ASPEN study ≥1 year after transitioning to zanubrutinib First results from a phase 1, first-in-human study of Bruton's tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) B-cell malignancies Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma (R/R FL) treated with zanubrutinib+ obinutuzumab versus obinutuzumab monotherapy: the ROSEWOOD trial Impact of real-world treatment sequencing patterns on time to next treatment among patients with chronic lymphocytic leukemia in the United States Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated with high response rates in patients with relapsed/refractory marginal zone lymphoma: data from an ongoing phase 1 study Number needed to treat analyses of zanubrutinib in relapsed/refractory chronic lymphocytic leukemia Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns among patients with chronic or small lymphocytic leukemia (CLL/SLL) in US community oncology practices Real-world evaluation of treatment discontinuation and healthcare resource utilization in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma Real-world patterns of care and financial burden of patients with follicular lymphoma in the United States Real-world switching pattern, persistence, and associated healthcare resource utilization of Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma in the United States Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison Tislelizumab, an anti-PD1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: a prospective multicenter Lysa phase 2 study conducted in Western countries Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies

Abstracts

A phase 4, observational study evaluating the efficacy and safety of the Bruton tyrosine kinase inhibitor (BTKi) zanubrutinib in patients with Waldenström macroglobulinemia (WM) Acquired mutations in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) that progressed in the ALPINE study Broad superiority of zanubrutinib (zanu) over bendamustine + rituximab (BR) across multiple high-risk factors: Biomarker subgroup analysis in the phase 3 SEQUOIA study in patients with treatment-naive (TN) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without del(17p) Clinical outcomes in patients with Waldenström macroglobulinemia (WM) receiving ibrutinib on the phase 3 ASPEN study ≥1 year after transitioning to zanubrutinib Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 inhibitor, and zanubrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is well tolerated and achieves deep responses in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (TN-CLL/SLL): data from an ongoing phase 1/2 study Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) First results from a phase 1, first-in-human study of Bruton's tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) B-cell malignancies Genomic landscape of ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies treated with zanubrutinib in a phase 2 study Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma (R/R FL) treated with zanubrutinib+ obinutuzumab versus obinutuzumab monotherapy: the ROSEWOOD trial Impact of real-world treatment sequencing patterns on time to next treatment among patients with chronic lymphocytic leukemia in the United States Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated with high response rates in patients with relapsed/refractory marginal zone lymphoma: data from an ongoing phase 1 study Number needed to treat analyses of zanubrutinib in relapsed/refractory chronic lymphocytic leukemia Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns among patients with chronic or small lymphocytic leukemia (CLL/SLL) in US community oncology practices Real-world evaluation of treatment discontinuation and healthcare resource utilization in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma Real-world patterns of care and financial burden of patients with follicular lymphoma in the United States Real-world switching pattern, persistence, and associated healthcare resource utilization of Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma in the United States Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison Sonrotoclax (BGB-11417) in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma with t(11;14): safety, efficacy, and determination of recommended phase 2 dose Tislelizumab, an anti-PD1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: a prospective multicenter Lysa phase 2 study conducted in Western countries Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies Zanubrutinib vs FCR in fit treatment-naive patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison
December 2023

European Society of Medical Oncology Immuno-Oncology (ESMO-IO)

November 2023

European Society for Medical Oncology-Asia (ESMO-Asia)

European Society for Medical Oncology-Asia (ESMO-Asia)

November 2023 (Singapore)
November 2023

Australasian Gastro-Intestinal Trials Group (AGITG)

November 2023

International Society for Pharmacoeconomics and Outcomes Research - Europe (ISPOR-EU)

International Society for Pharmacoeconomics and Outcomes Research - Europe (ISPOR-EU)

November 2023 (Copenhagen, Denmark)

Posters

Bruton tyrosine kinase inhibitor (BTKi) monotherapy for the treatment of ‘high-risk’ patients with previously untreated chronic lymphocytic leukemia (CLL): a systematic literature review (SLR) Cost-minimization analysis (CMA) of Bruton tyrosine kinase inhibitors (BTKis) in adults with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) Cost-utility analysis (CUA) in chronic lymphocytic leukemia (CLL): Is COVID-19’s impact on national life tables important to consider? Global clinical, economic, health-related quality of life burden, and treatment outcomes in follicular lymphoma: a systematic review Incidence, prevalence, and clinical characteristics of patients with chronic lymphocytic leukemia (CLL) in Spain: natural language processing (NLP) analysis of electronic health records (EHRs) Psychometric validation of QLQ-OES18 in 2L esophageal squamous cell cancer (ESCC) patients treated with tislelizumab versus chemotherapy Q-TWiST analysis is back in the game in oncology clinical trial analysis: a recent trend Quality of life and economic burden of advanced non-small cell lung cancer in medium and small markets (MED&SM): a systematic literature review Targeted treatments for patients with relapsed and/or refractory (R/R) chronic lymphocytic leukemia (CLL): a systematic literature review (SLR) of randomized clinical trials (RCTs) The disease and economic burden of hepatocellular carcinoma in Australia Treatment patterns and adverse events (AEs) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in France, Italy, and the United Kingdom (UK) Unmet needs and evidence gaps in relapsed/refractory marginal zone lymphoma: findings from a systematic literature review

Abstracts

Bruton tyrosine kinase inhibitor (BTKi) monotherapy for the treatment of ‘high-risk’ patients with previously untreated chronic lymphocytic leukemia (CLL): a systematic literature review (SLR) Cost-minimization analysis (CMA) of Bruton tyrosine kinase inhibitors (BTKis) in adults with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) Cost-utility analysis (CUA) in chronic lymphocytic leukemia (CLL): Is COVID-19’s impact on national life tables important to consider? Global clinical, economic, health-related quality of life burden, and treatment outcomes in follicular lymphoma: a systematic review Incidence, prevalence, and clinical characteristics of patients with chronic lymphocytic leukemia (CLL) in Spain: natural language processing (NLP) analysis of electronic health records (EHRs) Psychometric validation of QLQ-OES18 in 2L esophageal squamous cell cancer (ESCC) patients treated with tislelizumab versus chemotherapy Q-TWiST analysis is back in the game in oncology clinical trial analysis: a recent trend Quality of life and economic burden of advanced non-small cell lung cancer in medium and small markets (MED&SM): a systematic literature review Targeted treatments for patients with relapsed and/or refractory (R/R) chronic lymphocytic leukemia (CLL): a systematic literature review (SLR) of randomized clinical trials (RCTs) The disease and economic burden of hepatocellular carcinoma in Australia Treatment patterns and adverse events (AEs) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in France, Italy, and the United Kingdom (UK) Unmet needs and evidence gaps in relapsed/refractory marginal zone lymphoma: findings from a systematic literature review
November 2023

Portuguese Society of Hematology (SPH)

November 2023

BLOOD Annual Scientific Meeting (BLOOD)

BLOOD Annual Scientific Meeting (BLOOD)

November 2023 (Melbourne, Australia)

Abstracts

A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with NHL, or Waldenström macroglobulinemia (WM): preliminary data Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database Health-related quality of life (HRQOL) in patients with Waldenström macroglobulinemia (WM) treated with zanubrutinib or ibrutinib: results from long-term follow-up of the phase 3 ASPEN trial Incidence, prevalence, and mortality of Waldenström macroglobulinemia (WM) in Australia Incidence, prevalence, and mortality of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Australia Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA (BGB-3111-214) trial Zanubrutinib demonstrates superior progression-free survival (PFS) vs ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): final analysis of randomized phase 3 ALPINE study Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQOL)
November 2023

American Society of Nephrology Kidney Week (ASN Kidney Week)

November 2023

Annual Meeting of the Japan Lung Cancer Society (JLCS)

October 2023

Spanish Society of Hematology and Hemotherapy (SEHH)

Spanish Society of Hematology and Hemotherapy (SEHH)

October 2023 (Sevilla, Spain)

Abstracts

Evaluation of treatment and safety patterns in patients with chronic lymphocytic leukemia (CLL) using natural language processing (NLP): perspective of a multicenter observational study in Spain Health-related quality of life in patients (pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (zanu) vs ibrutinib (ibr): phase 3 ASPEN trial long-term follow-up results MAHOGANY: phase III trial of zanubrutinib (Z) plus anti-CD20 antibodies against lenalidomide plus rituximab (L+R) in patients (pts.) with relapsed/refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL) (R/R) Phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib for CLL/SLL: preliminary data Phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib for NHL or Waldenström macroglobulinemia (WM): preliminary data Zanubrutinib (ZANU) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib (zanu) in relation to ibrutinib (ibr) improves PFS in patients with refractory/recurrent (R/R) CLL: final analysis of the ALPINE study Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
October 2023

Italian Society of Hematology (SIE)

Italian Society of Hematology (SIE)

October 2023 (Rome, Italy)

Abstracts

Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL) A phase 1 study with the novel B-cell lymphoma 2 (BCL-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with CLL/SLL: preliminary data A phase 1 study with the novel B-cell lymphoma 2 (BCL-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with non-Hodgkin lymphoma (NHL) or Waldenström macroglobulinemia (WM): preliminary data Health-related quality of life in patients (pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (zanu) vs ibrutinib (ibr): results from the phase 3 ASPEN trial long-term follow-up Long-term efficacy and safety of zanubrutinib (zanu) in patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients (pts) with relapsed or refractory (R/R) follicular or marginal zone lymphoma (FL or MZL) Updated safety and efficacy results of zanubrutinib (zanu) in patients with B-cell malignancies who are intolerant of ibrutinib (ibr) and/or acalabrutinib (aca) Zanubrutinib (zanu) demonstrates superior progression-free survival (PFS) vs ibrutinib (ibr) for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): final analysis of phase 3 ALPINE study Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
October 2023

Florida Society of Clinical Oncology Fall Session (FLASCO)

October 2023

European Society for Medical Oncology (ESMO)

European Society for Medical Oncology (ESMO)

October 2023 (Madrid, Spain)

Abstracts

AdvanTIG-203: phase 2 randomized, multicenter study of ociperlimab (oci) + tislelizumab (tis) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PDL1) positivity AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (oci) + tislelizumab (tis) with chemotherapy (ct) in patients (pts) with metastatic esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) AdvanTIG-202: phase 2 randomized, multicenter, open-label study of tislelizumab (tis) with or without ociperlimab (oci) in patients (pts) with previously treated recurrent/metastatic (r/m) cervical cancer (CC) AdvanTIG-206: phase 2 randomized open-label study of ociperlimab (oci) + tislelizumab (tis) + BAT1706 (bevacizumab biosimilar) Versus tis + BAT1706 in Patients (pts) with advanced hepatocellular carcinoma (HCC) Long-term follow-up of a phase 2 study of tislelizumab (tis) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors Pathological response to neoadjuvant tislelizumab (tis) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIa NSCLC patients (pts) in the phase 3 (Ph3) RATIONALE-315 trial Phase (Ph) 1/2 study of sitravatinib (sitra) alone or with tislelizumab (tis) in advanced hepatocellular carcinoma (HCC) and gastric/gastroesophageal junction cancer (GC/GEJC) Randomized, global, phase 3 study of tislelizumab (tis) + chemotherapy (chemo) vs placebo (pbo) + chemo as first-line (1l) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): final analysis results of the RATIONALE-305 study Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): updated results from a phase 1b/2 study
October 2023

Japan Society of Clinical Oncology (JSCO)

October 2023

German, Austrian, and Swiss Societies for Hematology & Medical Oncology (DGHO)

October 2023

Japanese Society of Hematology (JSH)

October 2023

international workshop on CLL (iwCLL)

international workshop on CLL (iwCLL)

October 2023 (Boston, Massachusetts, USA)
September 2023

International Myeloma Society (IMS)

September 2023

Sociedad Española de Oncología Médica (SEOM)

September 2023

Polish Society of Hematology and Transfusion Medicine (PTHiT)

September 2023

World Conference on Lung Cancer (WCLC)

September 2023

Korean Society of Medical Oncology (KSMO)

August 2023

Asia-Pacific Gastroenterology Cancer Summit (APGCS)

August 2023

International Society for Pharmacoepidemiology (ICPE)

August 2023

American Society of Clinical Oncology - Breakthrough (ASCO Breakthrough)

American Society of Clinical Oncology - Breakthrough (ASCO Breakthrough)

August 2023 (Yokohama, Japan)
July 2023

Translational Summit on Hematologic Malignancies (DAVA Oncology Meetings)

June 2023

World Congress on Gastrointestinal Cancer (WCGI)

June 2023

Health Technology Assessment international (HTAi)

June 2023

European Association for the Study of the Liver (EASL)

June 2023

International Conference on Malignant Lymphoma (ICML)

International Conference on Malignant Lymphoma (ICML)

June 2023 (Lugano, Switzerland)

Abstracts

A meta-analytic endpoint validation of surrogates used in clinical trials evaluating the efficacy of therapies in patients with chronic lymphocytic leukemia (CLL) A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL First interim analysis of a phase 1 study of zanubrutinib (zanu) + lenalidomide (len) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE Long-term efficacy and safety of zanubrutinib (ZANU) in relapsed/refractory marginal zone lymphoma (R/R MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 versus lenalidomide plus rituximab in patients with relapsed/refractory follicular or marginal zone lymphoma Matching-adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) vs ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL) Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) CLL/SLL: extended follow-up of the SEQUOIA study Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B-cell malignancies: Post hoc analysis of a large clinical trial safety database Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life
June 2023

European Hematology Association (EHA)

European Hematology Association (EHA)

June 2023 (Frankfurt, Germany)

Posters

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies BGB-16673, a BTK degrader, overcomes on-target resistance from BTK inhibitors and presents sustainable long-term tumor regression in lymphoma xenograft models Bruton tyrosine kinase (BTK) protein degrader BGB-16673 is less apt to cause, and able to overcome variable BTK resistance mutations compared to other BTK inhibitors Characterization of zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database Comparative efficacy of zanubrutinib versus rituximab in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC) First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Health-relayed quality of life in patients with Waldenström macroglobulinemia (WM) treated with zanubrutinib vs ibrutinib: results from the phase 3 ASPEN trial long-term follow-up Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial Matching-adjusted indirect comparison (MAIC) of zanubrutinib versus ibrutinib in relapsed/refractory marginal zone lymphoma (R/R MZL) Real-world treatment patterns of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma in community oncology practices in the United States Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)

Abstracts

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies BGB-16673, a BTK degrader, overcomes on-target resistance from BTK inhibitors and presents sustainable long-term tumor regression in lymphoma xenograft models Bruton tyrosine kinase (BTK) protein degrader BGB-16673 is less apt to cause, and able to overcome variable BTK resistance mutations compared to other BTK inhibitors (BTKi) Characterization of zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database Comparative efficacy of zanubrutinib (zanu) versus rituximab (rtx) in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC) Efficacy and safety of once daily (QD) vs twice daily (BID) zanubrutinib for patients with various B-cell malignancies: a comparative summary of clinical data and exposure-response analysis First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Health-related quality of life in patients (pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (zanu) vs ibrutinib (ibr): results from the phase 3 ASPEN trial long-term follow-up Long-term efficacy and safety of zanubrutinib (zanu) in patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma Matching-adjusted indirect comparison (MAIC) of zanubrutinib (zanu) versus ibrutinib (ibru) in relapsed/refractory marginal zone lymphoma (R/R MZL) Persistence with oral therapy as reflection of actual compliance for chronic lymphocytic leukemia (CLL) - a national prescribed drug and patient registered study from Sweden Real-world treatment patterns of Bruton tyrosine kinase inhibitors (BTKi) in patients with mantle cell lymphoma (MCL) in community oncology practices in the United States (US) The meta-analytic endpoint validation of surrogates used in clinical trials evaluating the efficacy of therapies in patients with chronic lymphocytic leukemia Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
June 2023

American Society of Clinical Oncology (ASCO)

American Society of Clinical Oncology (ASCO)

June 2023 (Chicago, Illinois, USA)

Posters

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC) First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS) MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): the RATIONALE-301 European/North American (EU/NA) subgroup Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a phase Ib/II study Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed or refractory follicular lymphoma: updated analysis of the ROSEWOOD study

Abstracts

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC) Comparative efficacy of zanubrutinib (ZANU) versus rituximab (RTX) in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC) First interim analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS) MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma Matching-adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL) Real-world treatment patterns of Bruton tyrosine kinase inhibitors (BTKi) in patients with mantle cell lymphoma (MCL) in community oncology practices in the United States (US) Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: zanidatamab in previously- treated HER2-amplified biliary tract cancer (BTC) Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): the RATIONALE-301 European/North American (EU/NA) subgroup Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a Phase Ib/II study Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
May 2023

International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

April 2023

British Society for Haematology (BSH)

British Society for Haematology (BSH)

April 2023 (Birmingham, England)
April 2023

American Association for Cancer Research (AACR)

American Association for Cancer Research (AACR)

April 2023 (Orlando, Florida, USA)
March 2023

French Society of Hematology (SFH)

French Society of Hematology (SFH)

March 2023 (Paris, France)
March 2023

Hematology/Oncology Pharmacy Association (HOPA)

March 2023

Whistler Summit on Hematologic Malignancies (DAVA Oncology Meetings)

March 2023

American Society for Clinical Pharmacology & Therapeutics (ASCPT)

March 2023

Francophone Days of Hepato-gastroenterology and Digestive Oncology (JFHOD)

March 2023

Japanese Society of Medical Oncology (JSMO)

February 2023

International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma (ICHM )

February 2023

American Society of Clinical Oncology - Genitourinary Cancers Symposium (ASCO-GU)

February 2023

Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem)

January 2023

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (ASCO-GI)

December 2022

American Society of Hematology (ASH)

American Society of Hematology (ASH)

December 2022 (New Orleans, Louisiana, USA)

Abstracts

A phase 1 study evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies: preliminary data A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with non-Hodgkin lymphoma or Waldenström macroglobulinemia (WM): preliminary data A phase 1 with the novel B-cell lymphoma 2 (Bcl-1) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with CLL/SLL: preliminary data Biomarker analysis of zanubrutinib and tislelizumab combination therapy in patients with relapsed/refractory B-cell malignancies Development of hypertension and atrial fibrillation following diagnosis of B-cell malignancies - a retrospective analysis of US MarketScan insurance claims database Efficacy and safety of zanubrutinib in Japanese patients with mature B-cell malignancies Genomic characterization of patients in a phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients with relapsed/refractory B-cell malignancies Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial Long-term outcomes of second-line vs later-line zanubrutinib treatment in patients with relapsed/refractory MCL: an updated pooled analysis Preliminary safety and efficacy of BGB-11417, a novel Bcl-2 inhibitor, in combination with azacitidine in patients with acute myeloid leukemia (AML) Preliminary safety and efficacy of zanubrutinib in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Preliminary safety of a Bcl-2 inhibitor, BGB-11417, in patients with relapsed/refractory multiple myeloma harboring t(11,14): a non-randomized, open-label, phase 1b/2 study Real-world evidence (RWE) studies supported hematologic oncology United States Food and Drug Administration (US FDA) approval: what do they look like? Zanubrutinib demonstrates superior progression-free survival (PFS) compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): results from final analysis of ALPINE randomized phase 3 study Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies
December 2022

European Society of Medical Oncology Immuno-Oncology (ESMO-IO)

European Society of Medical Oncology Immuno-Oncology (ESMO-IO)

December 2022 (Geneva, Switzerland)
December 2022

European Society for Medical Oncology-Asia (ESMO-Asia)

European Society for Medical Oncology-Asia (ESMO-Asia)

December 2022 (Singapore)
November 2022

German Cancer Congress (DKK)

November 2022

Korean Association for Lung Cancer (KALC)

November 2022

Society for Immunotherapy of Cancer (SITC)

November 2022

Portuguese Society of Hematology (SPH)

November 2022

International Society for Pharmacoeconomics and Outcomes Research - Europe (ISPOR-EU)

November 2022

Chinese Society of Clinical Oncology (CSCO)

Chinese Society of Clinical Oncology (CSCO)

November 2022 (China)